RIBOMIC Inc. announced that the first dose of RBM-007 (anti-FGF2 aptamer) was administered to a pediatric patient with Achondroplasia in the early phase II study to investigate the efficacy and safety of RBM-007. RBM-007 is a novel nucleic acid medicine (oligonucleotide-based aptamer) developed in-house at RIBOMIC's research facilities in Tokyo. RBM-007 has been shown to have potent effects in limiting excessive interactions between fibroblast growth factors, which are known to cause achondroplasia.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
85 JPY | 0.00% | +1.19% | -21.30% |
1st Jan change | Capi. | |
---|---|---|
-21.30% | 19.56M | |
+5.33% | 111B | |
+12.11% | 106B | |
-12.56% | 22.24B | |
-3.17% | 21.25B | |
-5.71% | 18.97B | |
-35.21% | 18.52B | |
-10.86% | 16.81B | |
+37.57% | 12.54B | |
-26.24% | 8.09B |
- Stock Market
- Equities
- 4591 Stock
- News Ribomic Inc.
- RIBOMIC, Inc. Announces Start of Administration of RBM-007, Achondroplasia Investigational Drug, to the First Patient in the Early Phase II Study in Japan